Verenium Corporation's CEO Discusses Q1 2012 Results - Earnings Call Transcript
The company’s actual results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in our filings with the SEC, including, but not limited to, our report on Form 10-K for the year ended December 31st, 2011, and in our subsequently filed quarterly reports on form 10-Q. These forward-looking statements speak only as of the date hereof.
And I will now turn the call over to Jamie.
Thanks Jeff. And good afternoon everyone, and thanks for joining us. I’d like to start with a few comments regarding the recent transaction with DSM. As you know, in March we announced that DSM has acquired certain commercial and pipeline products for a total consideration of $37 million. And I’d like to add two observations to the comments that we made at the time of the announcement.First, you’ve heard us talk in the past about how our technology can create the highest-performing enzymes. Our sale of Purifine shows a global player like DSM clearly agreed with the substance of our claim. However, for our current portfolio, the same performance advantage is also true. Fuelzyme, our high-performance product for corn bioethanol, has a fundamentally different mode of action compared to competitors’ enzymes, and Janet will describe how this has allowed us to grow our sales of Fuelzyme in a very challenging period for corn bioethanol. The second observation I’d make about the DSM deal is that a number of global companies we’ve met with in the past several weeks have emphasized that they’ve had a longstanding interest in accessing Verenium’s technology, but also a concern about the impact of the convertible notes on our financial health. With the debt now behind us, we’re finding that opportunities for partnering have expanded.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV